The high-grade NMIBC pipeline possesses potential drugs in mid and late-stage developments to be launched in the near future. The major key players include Urogen Pharma, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, and others that hold the potential to create a significant positive shift in NMIBC in the market size and the treatment scenario.
DelveInsight’s “Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Muscle Invasive Bladder Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Non-Muscle Invasive Bladder Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Non-Muscle Invasive Bladder Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Non-Muscle Invasive Bladder Cancer (NMIBC): An Overview
Non-muscle invasive bladder cancer (NMIBC) is cancer of the bladder. NMIBC is a cancer that grows only in the thin tissue on the inside surface of the bladder. With NMIBC, the bladder muscle is not involved, and the tumor does not spread outside the bladder.
There are a number of things that may increase the risk of getting bladder cancer including smoking, working in places that make plastics, paints, leather, and rubber, cancer drugs, radiation to the pelvis, and genes. Blood in the urine is the most common symptom of bladder cancer, which is often painless. Other symptoms of NMIBC include frequent and urgent urination, pain when you pass urine, pain in your lower abdomen, and back pain.
The best treatment for NMIBC is early diagnosis and early care. Treatment will also depend on the stage and the growth of cancer. Treatments for non-muscle invasive bladder cancer include cystoscopic transurethral resection of the bladder tumor (TURBT), intravesical therapy, and surgery. If these options fail to treat the cancer, your doctor may recommend removing the complete bladder.
FDA has approved many drugs for the treatment of bladder cancer but to date there are only two drugs which are being given for the treatment of NMIBC which include KEYTRUDA and ADSTILADRIN, approved in 2020 and 2022, respectively.
Non-Muscle Invasive Bladder Cancer Market Key Facts
-
The total prevalent cases of Bladder Cancer in the US were approximately 800,000 cases in 2022.
-
As per DelveInsight’s estimates, in the US, low-risk NMIBC patients were higher as compared to the high-risk NMIBC patients in 2022.
-
EU4 and the UK had the highest number of diagnosed prevalent cases of NMIBC among the 7MM. In 2022, EU4 and the UK accounted for approximately 250,000 cases.
-
Age-specific incidence of NMIBC cancer increased from 5.52 to 9.09 per 100,000 from 1998 to 2006, as reported in a population-based study on the US population (Nelisen et al., al 2014)
-
Bladder Cancer is more common in males than females.
-
In 2022, total tumor stage-specific diagnosed prevalent cases of NMIBC in Japan for stages Ta, Tis, and T1 were around 50,000, 2,543, and 25,000, respectively.
Non-Muscle Invasive Bladder Cancer (NMIBC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Non-Muscle Invasive Bladder Cancer pipeline therapies. It also thoroughly assesses the Non-Muscle Invasive Bladder Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Non-Muscle Invasive Bladder Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Non-Muscle Invasive Bladder Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Non-Muscle Invasive Bladder Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Non-Muscle Invasive Bladder Cancer Epidemiology, Segmented as –
-
Prevalent cases of Bladder Cancer in the 7MM (2019-2032)
-
Age-specific Diagnosed Prevalence of NMIBC in the 7MM (2019-2032)
-
Diagnosed Prevalent cases of NMIBC in the 7MM (2019-2032)
-
Tumor stage-specific Diagnosed Prevalence of NMIBC in the 7MM (2019-2032)
-
Risk-specific Diagnosed Prevalence of NMIBC in the 7MM (2019-2032)
-
Grade-specific Diagnosed Prevalence of NMIBC in the 7MM (2019-2032)
Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Non-Muscle Invasive Bladder Cancer market or expected to be launched during the study period. The analysis covers the Non-Muscle Invasive Bladder Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Non-Muscle Invasive Bladder Cancer drugs based on their sale and market share.
The report also covers the Non-Muscle Invasive Bladder Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Non-Muscle Invasive Bladder Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Non-Muscle Invasive Bladder Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market
Non-Muscle Invasive Bladder Cancer (NMIBC) Therapeutics Analysis
NMIBC remains a very challenging disease to treat, with high rates of recurrence and progression associated with current therapies. The high rates of progression and recurrence with current therapies for NMIBC necessitate lifelong active surveillance, making bladder cancer the most expensive cancer to treat from diagnosis to death, as well as driving the need for the development of new therapies in patients with NMIBC.
The current treatment regimen includes KEYTRUDA (pembrolizumab), ADSTILADRIN, surgery, intravesical immunotherapy (BCG), and intravesical chemotherapy. Intermediate- or high-risk NMIBC is generally treated with transurethral resection of bladder tumor (TURBT), followed by adjuvant BCG immunotherapy which is the gold standard treatment for reducing tumor recurrence rates and preventing subsequent stage progression. Stage 0 bladder cancer is most often treated with TURBT with fulguration followed by intravesical therapy within 24 h. Sometimes no further treatment is needed. Cystoscopy is then done every 3–6 months to watch for signs that cancer has come back. Valrubicin might be used if BCG stops working. However, not all experts agree on this treatment.
Several major pharma and biotech giants are developing therapies for Non-Muscle Invasive Bladder Cancer. Currently, UroGen Pharma is leading the therapeutics market with its Non-Muscle Invasive Bladder Cancer drug candidates in the most advanced stage of clinical development.
In December 2022, US FDA approved ADSTILADRIN (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Non-Muscle Invasive Bladder Cancer (NMIBC) Companies Actively Working in the Therapeutics Market Include
Abraxis Bioscience, Asieris Pharmaceuticals, AstraZeneca, CG Oncolgy, Hamlet Pharma, ImmunityBio, Incyte Corporation, Janssen Pharmaceuticals, LIPAC Oncology, Prokarium, Rapamycin Holdings, Sasanlimab, Sesen Bio, Taizhou Hanzhong biomedical, Theralase Technologies, Vaxiion Therapeutics, Viralytics, UroGen Pharma, and many more.
Emerging and Marketed Non-Muscle Invasive Bladder Cancer (NMIBC) Therapies Covered in the Report Include:
Adstiladrin(nadofaragenefiradenovec/Syn3): FKD Therapies Oy/Ferring Pharmaceuticals, APL-1202: Asieris Pharmaceuticals, CG0070: CG Oncology, EG-70: enGene, Erdafitinib: Janssen Pharmaceuticals, Keytruda: Merck, N-803 (ALT-803): ImmunityBio/Altor Biosciences, PF-06801591: Pfizer, Sasanlimab (PF-06801591): Pfizer, TARA-002: Protara Therapeutics, TECENTRIQ: Roche, TL-532: Tollys, TLD 1433: Theralase Technologies, UGN-102: UroGen Pharma, VAX 014: Vaxiion Therapeutics, Vicinium: Viventia Bio/Sesen Bio, KEYTRUDA (pembrolizumab): MSD, ADSTILADRIN (nadofaragene firadenovec-vncg): Ferring Pharmaceuticals, and many more.
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Non-Muscle Invasive Bladder Cancer Competitive Intelligence Analysis
4. Non-Muscle Invasive Bladder Cancer Market Overview at a Glance
5. Non-Muscle Invasive Bladder Cancer Disease Background and Overview
6. Non-Muscle Invasive Bladder Cancer Patient Journey
7. Non-Muscle Invasive Bladder Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Non-Muscle Invasive Bladder Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Muscle Invasive Bladder Cancer Unmet Needs
10. Key Endpoints of Non-Muscle Invasive Bladder Cancer Treatment
11. Non-Muscle Invasive Bladder Cancer Marketed Therapies
12. Non-Muscle Invasive Bladder Cancer Emerging Drugs and Latest Therapeutic Advances
13. Non-Muscle Invasive Bladder Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Non-Muscle Invasive Bladder Cancer Market Outlook (In US, EU5, and Japan)
16. Non-Muscle Invasive Bladder Cancer Companies Active in the Market
17. Non-Muscle Invasive Bladder Cancer Access and Reimbursement Overview
18. KOL Views on the Non-Muscle Invasive Bladder Cancer Market
19. Non-Muscle Invasive Bladder Cancer Market Drivers
20. Non-Muscle Invasive Bladder Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Graves Orbitopathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Graves Orbitopathy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Graves Orbitopathy market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology